Rare Disease business comes in slightly below expectations for Novo Nordisk
Though hemophilia drug Novoseven surprised positively in Q4, Novo’s Rare Disease segment was let down by its treatments for rare endocrine disorders.
by marketwire, translated by daniel pedersen
Novo Nordisk’s sales of hemophilia drug Novoseven surprised positively in Q4’22, revealed the Danish drugmaker’s annual report for 2022 on Wednesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk predicts wide range for 2023 sales growth
For subscribers
Novo Nordisk doubles obesity sales in 2022
For subscribers
.jpg&w=384&q=75)
